Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
ADA 2021: Finerenone in the Chronic Kidney Disease and Diabetes Population
Can Physical Activity Improve Cognitive Function?
MOST POPULAR ARTICLES OF THE MONTH
#1 Here We Go Again: The Low-Carb vs. High-Carb and Training Debate
#2 ADA 2021: A Promising Future for Tirzepatide
#3 ADA 2021: Economic Benefits of Initiating Empagliflozin vs. GLP-1 Receptor Agonist
Letter from the Editor
Luseogliflozin is an SGLT-2 inhibitor that has been available since 2014 in Japan, but has never been released in the US. Based on a study that our intern, Torré Anderson, II, Fourth Year Doctor of Pharmacy Candidate, Florida A&M University College of Pharmacy, has for us this week, it may be possible that the company is thinking about making a US entrance.
His feature looks at how changing from a DPP4-I to this SGLT-2 inhibitor can make a big difference in hypertension and related heart problems. Take a look at his article and make a choice as to whether you think the effects are limited to this medication or class wide.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
TOP STORIES — Diabetes News and Research
Finerenone is a mineralocorticoid receptor antagonist indicated for chronic kidney disease (CKD) with type 2 diabetes. Does the use of insulin affect its performance against kidney and cardiovascular issues?
Researchers investigate the changes in ambulatory blood pressure using the antidiabetic drug in patients with type 2 diabetes and hypertension.
A meta-analysis was conducted to determine the impact of physical activity on cognition improvement in patients with diabetes.